A B S T R A C T The paroxysmal nocturnal hemoglobinuria (PNH) platelet differs from the normal human platelet in its interaction with activated complement components: (a) when complement is activated by the alternative pathway, greater amounts of C3 are fixed to the PNH platelet than to the normal platelet; (b) the platelet-release reaction, as measured by serotonin release, occurs after C3 fixation to the PNH platelet. This reaction does not occur with normal platelets; (c) although serotonin release mediated by antibody alone was the same for normal and PNH platelets, antibody-initiated complement activation resulted in the fixation of greater amounts of C3 to PNH platelets and greater consequent serotonin release; and (d) nearly maximal serotonin release from PNH platelets occurs after the fixation of C3 (or perhaps C5) to the membrane without completion of the terminal sequence. In contrast, completion of the terminal complement sequence beyond C5 is required for maximal serotonin release from normal platelets. These abnormalities of interaction of complement components and PNH platelets may explain the occurrence of thromboses in this disease.
INTRODUCTION
Antiplatelet antibody from a number of sources has been shown to interact with platelets and to fix complement to the platelet surface. The result of this interaction is activation of the platelet, release of vasoactive amines, and possibly platelet lysis (1) (2) (3) . Zymosan, a substance known to activate the Receivedfor publication 25 Apr1l 1975 and in revisedform 22 October 1976. alternative pathway of complement, will produce similar reactions but only in the presence of plasma (4, 5) . These reactions are readily demonstrated with rabbit platelets (6) (7) (8) (9) (10) , and the activation of complement has been thought to result in intravascular coagulation in these experimental animals (11) . Normal human platelets, however, are markedly unresponsive in these reactions and do not readily release serotonin or platelet factor 3 when complement is activated (4, 12, 13) .
Patients with paroxysmal nocturnal hemoglobinuria (PNH)l are particularly prone to the development of serious thrombotic disease, frequently in association with severe hemolytic episodes. These episodes are thought to be due to activation of complement, and hemolysis is thought to occur because a portion of the red cells of patients with PNH are abnormal in that they bind more complement and are lysed more readily than are normal erythrocytes (14) . Thus the cells are lysed by smaller amounts of activated complement in vivo.
Increased complement-mediated lysis of PNH platelets has been demonstrated in vitro (15) , but activation of the platelet has not been investigated in PNH. If the platelet membrane had a defect like that of the red cell, the sensitivity to complement might also manifest itself by increased activation, much like the rabbit platelet. If this were true, the increased thrombosis seen in these patients might be related to some membrane defect.
In the present investigation, we used release of ['4C]serotonin as a measure of platelet activation (16) . We showed that activation of the complement sequence by either the classic or the alternative pathways does indeed activate the release of serotonin more readily in PNH than normal platelets. This is in part due to the fixation of greater amounts of complement components. thus, the membrane abnormality of the platelets is probably similar to that of the erythrocytes and may account for the increased thromboses seen in these patients.
METHODS
Platelets. 10 patients with PNH (defined by increased sensitivity of erythrocytes to antibody-mediated complement lysis) were studied on multiple occasions. All patients were receiving up to 30 mg of prednisone on an alternate day basis, and none were significantly thrombocytopenic. The normal platelets were obtained from healthy, age-matched volunteers. Blood from all subjects was collected in plastic containers and anticoagulated with 10%o EDTA. Platelets were prepared by differential centrifugation, washed four times in isotonic EDTAVeronal-buffered saline (VBS), and resuspended in VBS containing calcium and magnesium with gelatin or in platelet-poor plasma. Serial dilutions of platelets were counted by phase microscopy.
Buffers and complement reagents. VBS, buffered 0.015 M and 0.1 M EDTA acid and disodium salt (EDTA-VBS) were prepared (9) . Serum prepared from whole blood at 370C was stored at -90°C and used as a complete complement source. Purified human Cl and C2 were prepared as previously described (17) . Highly purified human C3 and rabbit anti-human C3 were prepared (10) . Partially purified cobra venom factor (CoF) was obtained from Sephadex G-100 (Pharmacia Fine Chemicals Inc., Piscataway, N. J.) (18) . CoF-activated serum was prepared by incubation of purified CoF with normal human serum as described by Kabakgi et al. (19) . Serum Measurement of surface-bound C3 and IgG. The quantity of C3 on the surface of platelets was determined by the anti-C3 absorption technique of Borsos and Leonard (22) as modified by Rosse et al. (18) . Sheep cells coated with human C3 were prepared by incubation in normal human serum, washed, and reacted with 0.02 M 2-mercaptoethanol. Anti-C3 was made in rabbits according to the method described (23 (Fig. 1) .
CoF-activated serum is ineffective in causing serotonin release from normal platelets but is effective in doing so from PNH platelets. The relationship between C3 fixation and serotonin release is shown in Fig. 2 . The fourfold increment in membrane C3 fixation to PNH platelets resulted in proportional increase in serotonin release from these platelets. CoF alone or cobra venom-activated serum alone (depleted of C3, C5, C6, C7, C8, and C9) produced no increment in membrane C3 or serotonin release from normal or PNH platelets.
Acidified serum-mediated activation. As shown in Fig. 3 , substitution of dilutions of serum at pH 6.4, in the reaction mixture results in a fourfold increase in C3 measurable on the PNH platelet surface but no appreciable increase in C3 on normal platelets. Similarly, a proportionally greater amount of serotonin release from PNH platelets is observed (Fig.  4) . In no instance did acidified serum or isotonic buffer, pH 6.4, effect a measurable increment in serotonin release from normal platelets.
C3b-mediated activation. The active component of C3, C3b, was prepared from purified human complement components. Sheep red cells were coated with C4 by the method of Borsos C3 was fixed to PNH platelets as compared to normal platelets.
Similar results were obtained using serum from patients with drug-induced purpura (three instances of quinidine and one of codeine-induced thrombocytopenia [ Table I When the amount of membrane-bound C3 was compared to the degree of serotonin release, the increased serotonin release from PNH platelets paralleled the greater C3 fixation on the PNH platelets (Fig. 7) . The C3 fixed was no more effective in causing serotonin release from PNH than from normal platelets; the increased serotonin release by PNH platelets was related to greater amounts of membrane C3 fixed at any antibody dilution.
Kinetics of antibody-mediated release. To assess the role of complement in the antibodymediated release reaction, the response of normal and PNH platelets was studied over time (Fig. 8) [20] ) results in 25-30%o release of serotonin during the first few minutes and a subsequent increase to 40%o over the next 20 min. The amount of serotonin released is identical at each time point in the two groups of platelets.
In a second phase of the reaction, when a complement-fixing antibody is used,increasing amounts of C3 are detectable on the membrane and a further increment in serotonin release is observed. After 30 min, C3 has been bound to PNH platelets and more serotonin has been released. With each complement-fixing antibody studied, serotonin was released from PNH platelets only after significant increment in membrane-bound C3; i.e., after 2 min of reaction.
To study the role of the terminal complement components beyond C5 in the release reaction, purified anti-I antibody was reacted with platelets and C6-deficient serum was employed as a complement source. The C6-deficient serum did not cause serotonin release from normal platelets unless purified C6Iru was added to the reaction (Table II) . In contrast, when PNH platelets were studied, appreciable release occurred in C6-deficient serum and a 10-15% further increment in release occurred when purified C61"u was added back to the reaction. The terminal components of complement beyond C5 are not required for a release reaction detectable at 30 min from PNH platelets activated by antibody. A further slight increase in serotonin release may be observed at 30 min, however, when all terminal components are present.
DISCUSSION
In the rabbit, a role for complement in platelet activation has been well established (17) . Rabbit platelets undergo a two-stage reaction with soluble antigen-antibody complexes. The first, requiring complement components through C3, results in platelet aggregation. The second, requiring completion of the sequence through C6, results in the release reaction (12) . Similarly, agents known to interact with the components of the alternative pathway of complement activation cause rabbit platelets to undergo the release reaction subsequent to the activation of C3 (26) .
In the present work, we have investigated the role of complement in the activation of human platelets from both normal donors and patients with PNH. sensitive and reproduceable (18, 20) . Determination of radiolabeled serotonin release has been shown to be an accurate means of assessing the plateletrelease reaction (16) . These methods were used in the study of the individual steps in this reaction. There appear to be several mechanisms by which activation of complement by antibody activates serotonin release from platelets. From the kinetic studies with antibody, two separate phases of serotonin release from normal and PNH platelets have been identified. The first phase occurs within the first 2 min of incubation and appears to be due to interaction with antibody. Release of serotonin in this phase is equal in normal and PNH platelets and occurs independently of the presence of complement, as judged by detectable C3 on the membrane. This reaction occurs without increment in membrane-bound C3, and the proportion of serotonin released is identical in reactions employing both complement-fixing and noncomplement-fixing antibodies. Pfueller and Luscher have suggested this involves direct interaction of antibody (probably Fc fragment) and platelet surface (13) . With PNH platelets, complement-dependent efflux of serotonin appears to result from two mechanisms of complement-platelet interaction: one due to C3 or C5 fixation, the other requiring fixation of terminal complement sequences beyond C5. As with the PNH erythrocyte, greater amounts of C3 are fixed to the membrane of the PNH platelet than to the normal platelet. The activation of C3 and C5, and its fixation to the membrane of the PNH platelet, result in release of serotonin even in the absence of terminal complement components, as shown with C6-deficient serum. This reaction does not appear to occur with normal platelets. The second mechanism which results in a further efflux of serotonin from PNH platelets does not occur in the absence of C6 and presumably requires the terminal components of complement. This release is probably the result of membrane damage evoked by the terminal C' components. This occurs with normal platelets as well as PNH platelets. At present this cannot be confirmed as we do not have available a measure of lysis due to completion of the complement sequence.
In the experiment using purified components of complement in the generation of C3b, no C3b was detected on the platelet membrane but release of serotonin occurred. This may be due to insensitivity of the assay for the detection of C3b. Less C3 may be fixed in the system than in systems in which whole serum is present because, in the latter, bound C3 may bind activated factor B of the alternative pathway (27) . This complex is capable of generating superfluous C3b at the membrane surface which would be more readily detectable in the assay.
Alternatively, the release reaction might be mediated by other proteins in the solution. Since the C3 used in these experiments was "pure" by electrophoretic and immunologic criteria, and since the reaction did not occur when this protein was omitted, the material responsible for the release reaction would have to be C3b or C3a. Previous experiments in other systems would indicate that C3b was responsible for this release reaction.
In contrast to antibody-mediated complement activation, fluid-phase complement activation through the alternative pathway results in serotonin release from PNH but not from normal platelets. Activation of this pathway by acidification of serum or treatment with CoF-activated serum results in the fixation of up to 10 fg of C3 to PNH platelets and a 10-fold increase in serotonin release, but no appreciable C3 fixation or serotonin release from normal platelets. A portion of the observed serotonin efflux from PNH platelets may well be due to platelet lysis as evidenced by the requirement for C6 to effect maximal serotonin release. However, C3 or C5 activation in the absence of terminal complement components is sufficient for serotonin release from PNH platelets. The maximal release of serotonin from platelets with C3b but without the terminal components was 50%o. In contrast, when acidified or CoF-activated serum containing all C components was supplied, the proportion of serotonin released was invariably greater than 75%. Thus it is probable that C3b alone in fluid phase is capable of activating PNH platelets, resulting in serotonin release but that the further increment in serotonin release (25%) is either a result of platelet lysis after completion of complement sequences on the platelet membrane or a result of platelet interaction with other serum proteins. In contrast, the fluid-phase C3b does not bring about release of serotonin from normal platelets. Aster and Enright showed that the PNH platelet, like the PNH red cell, is more sensitive to lysis by complement that its normal counterpart (15) . The present data demonstrate that this is in part due to an increase in the amount of C3 which is fixed to the platelet membrane but the data also suggest that the terminal components of complement are more effective on PNH than on normal platelets in effecting membrane damage. Similar differences have been found between normal and the markedly abnormal variety of PNH red cells (18) . It is not clear from these present studies or those of Aster and Enright (15) whether the platelets in PNH, like the red cells, consist of different populations with respect to complement sensitivity.
Activation of the platelet as manifest by serotonin release may be the mechanism by which increased thrombosis occurs in these patients, as originally suggested by Shulman et al. (21) . Most major thrombotic phenomena occur during periods of complement activation as manifest by hemolytic crises. Thus, the two major clinical manifestations of PNH, hemolysis and thrombosis, may have similar causes, an abnormal sensitivity to the effects of the "normal" activation of complement.
